Entrepreneurial Self-Efficacy of Scientists:A qualitative study on ATTRACT Phase 2 R&D&I Ventures

We need to understand the antecedents of entrepreneurial self-efficacy (ESE) of actors in science and technology-based commercialisation when we want to foster the commercialisation of scientific innovations. Despite the plethora of research on ESE in general, research on antecedents of ESE of scientists is scarce. Yet, there is reason to believe that because scientists develop a scientific self-efficacy, the antecedents to scientists’ entrepreneurial self-efficacy differ from the ESE antecedents of other target groups. Therefore, we explored which ESE antecedents resonate with a unique cohort of scientists and how attributes such as cultural and institutional factors, firm capabilities, education, work experience, role models, and individual differences support the building of entrepreneurial competence. This study provides practical relevance to educators and science entrepreneurs, identifying a need for tailored education for science and technology-based entrepreneurship to foster the development of a dual self-efficacy that reflects scientific norms and commercialisation needs.</p

When fragments link : a bibliometric perspective on the development of fragment-based drug discovery

Fragment-based drug discovery (FBDD) is a highly interdisciplinary field, rich in ideas integrated from pharmaceutical sciences, chemistry, biology, and physics, among others. To enrich our understanding of the development of the field, we used bibliometric techniques to analyze 3642 publications in FBDD, complementing accounts by key practitioners. Mapping its core papers, we found the transfer of knowledge from academia to industry. Co-authorship analysis showed that university–industry collaboration has grown over time. Moreover, we show how ideas from other scientific disciplines have been integrated into the FBDD paradigm. Keyword analysis showed that the field is organized into four interconnected practices: library design, fragment screening, computational methods, and optimization. This study highlights the importance of interactions among various individuals and institutions from diverse disciplines in newly emerging scientific fields. We study the organizational aspects of the development of fragment-based drug discovery (FBDD), using tools from bibliometrics

From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function

Chemokine receptors CXCR4 and atypical chemokine receptor 3 (ACKR3/CXCR7) are highly expressed in a range of tumors. Yet, their role in cancer progression is not well understood. This minireview series encompasses seven comprehensive reviews focusing on modulators (small molecules, pepducins, antibodies), structural aspects, spatio-temporal signaling properties, and phosphorylation/interactome of CXCR4 and ACKR3. Moreover, different (patho)physiologic aspects and roles of these receptors in immunologic and oncogenic processes are discussed. SIGNIFICANCE STATEMENT: CXCR4 and atypical chemokine receptor 3 are two oncogenic G protein-coupled receptors that are highly upregulated in various tumors. Insight into the signalling properties of these receptors and the availability of modulators targeting these receptors are essential to assess their role in cancer

Innovation in pharmaceutical R&amp;D:mapping the research landscape

In response to the increasing number and breadth of innovation studies on the pharmaceutical industry, we mapped the literature to show the trends in recent research and to indicate areas for further research. In the first phase, we analyzed articles on the pharmaceutical industry published in innovation journals. We used these articles’ textual and citation data and applied hybrid cluster analysis. Three main clusters were produced based on the level of analysis innovation scholars had used to investigate the industry: macro, meso and micro. We describe the research topics within these clusters and show that, overall, innovation scholars increasingly focus on the meso-level, analyzing the relationships across different firms. This shift in interest toward the collaborative nature of drug discovery and development was also apparent in macro- and micro-level studies. To explore how this literature is used by scientists in the industry, our second phase involved analysis of the citing articles published in pharmaceutical journals. Using our findings, we propose research areas that can be further explored in order to create an engaged and better-integrated literature on pharmaceutical innovation